Presence of tumor-infiltrating CD8⁺ T cells and macrophages correlates to longer overall survival in patients undergoing isolated hepatic perfusion for uveal melanoma liver metastasis

References

• Folberg R. The eye. 9th ed. Robbins & Cotran Pathologic Basis of Disease; 2014.  Elsevier: p. 1319–9.
   Google Scholar
• Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664–1678. doi:10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G.
   PubMed Web of Science ®Google Scholar
• Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no. 26. Arch Ophthalmol. 2005;123(12):1639–1643.
   PubMed Web of Science ®Google Scholar
• Lane AM, Kim IK, Gragoudas ES. Survival rates in patients after treatment for metastasis from uveal melanoma. JAMA Ophthalmol. 2018;136(9):981–986. doi:10.1001/jamaophthalmol.2018.2466.
   PubMed Web of Science ®Google Scholar
• Rantala ES, Hernberg M, Kivela TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29(6):561–568. doi:10.1097/CMR.0000000000000575.
   PubMed Web of Science ®Google Scholar
• Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122(21):3344–3353. doi:10.1002/cncr.30258.
   PubMed Web of Science ®Google Scholar
• Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meer M, Meier F, Terheyden P, Schell B, et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer. 2017;82:56–65. doi:10.1016/j.ejca.2017.05.038.
   PubMed Web of Science ®Google Scholar
• Ben-Shabat I, Belgrano V, Ny L, Nilsson J, Lindnér P, Olofsson Bagge R. Long-term follow-up evaluation of 68 patients with uveal melanoma liver metastases treated with isolated hepatic perfusion. Ann Surg Oncol. 2016;23(4):1327–1334. doi:10.1245/s10434-015-4982-5.
   PubMed Web of Science ®Google Scholar
• Olofsson R, Ny L, Eilard MS, Rizell M, Cahlin C, Stierner U, Lönn U, Hansson J, Ljuslinder I, Lundgren L, et al. Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. Trials. 2014;15(1):317. doi:10.1186/1745-6215-15-317.
   PubMedGoogle Scholar
• Olofsson R, Lindberg E, Karlsson-Parra A, Lindnér P, Mattsson J, Andersson B. Melan-A specific CD8+ T lymphocytes after hyperthermic isolated limb perfusion: a pilot study in patients with in-transit metastases of malignant melanoma. Int J Hyperthermia. 2013;29(3):234–238.
   Google Scholar
• Dudek-Peric AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Martin S, Kiviluoto S, Winiarska M, Boon L, Mathieu C, et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Res. 2015;75(8):1603–1614. doi:10.1158/0008-5472.CAN-14-2089.
   PubMed Web of Science ®Google Scholar
• Martner A, Johansson J, Ben-Shabat I, Bagge RO. Melphalan, antimelanoma immunity, and inflammation–letter. Cancer Res. 2015;75(24):5398–5399. doi:10.1158/0008-5472.CAN-15-1184.
   PubMed Web of Science ®Google Scholar
• Johansson J, Kiffin R, Andersson A, Lindnér P, Naredi PL, Olofsson Bagge R, Martner A. Isolated limb perfusion with melphalan triggers immune activation in melanoma patients. Front Oncol. 2018;8:570. doi:10.3389/fonc.2018.00570.
   PubMed Web of Science ®Google Scholar
• Johansson J, Kiffin R, Aydin E, Nilsson MS, Hellstrand K, Lindnér P, Naredi P, Olofsson Bagge R, Martner A. Isolated limb perfusion with melphalan activates interferon-stimulated genes to induce tumor regression in patients with melanoma in-transit metastasis. OncoImmunology. 2020;9(1):1684126. doi:10.1080/2162402X.2019.1684126.
   PubMed Web of Science ®Google Scholar
• Wong KL, Yeap WH, Tai JJY, Ong SM, Dang TM, Wong SC. The three human monocyte subsets: implications for health and disease. Immunol Res. 2012;53(1–3):41–57. doi:10.1007/s12026-012-8297-3.
   PubMed Web of Science ®Google Scholar
• Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. Immunology. 2013;140(1):22–30. doi:10.1111/imm.12117.
   PubMed Web of Science ®Google Scholar
• Ko HS, Fu SM, Winchester RJ, Yu DT, Kunkel HG. Ia determinants on stimulated human T lymphocytes. Occurrence on mitogen- and antigen-activated T cells. J Exp Med. 1979;150(2):246–255. doi:10.1084/jem.150.2.246.
   PubMed Web of Science ®Google Scholar
• Vogel DY, Glim JE, Stavenuiter AWD, Breur M, Heijnen P, Amor S, Dijkstra CD, Beelen RHJ. Human macrophage polarization in vitro: maturation and activation methods compared. Immunobiology. 2014;219(9):695–703. doi:10.1016/j.imbio.2014.05.002.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob -J-J, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. doi:10.1056/NEJMoa1709684.
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
   Google Scholar
• Terai M, Mastrangleo MJ, Sato T. Immunological aspect of the liver and metastatic uveal melanoma. J Cancer Metastasis Treat. 2017;3:231–243. doi:10.20517/2394-4722.2017.39.
   Google Scholar
• Rossi E, Schinzari G, Zizzari IG, Maiorano BA, Pagliara MM, Sammarco MG, Fiorentino V, Petrone G, Cassano A, Rindi G, et al. Immunological backbone of uveal melanoma: is there a rationale for immunotherapy? Cancers (Basel). 2019;11(8):1055. doi:10.3390/cancers11081055.
   PubMed Web of Science ®Google Scholar
• Gebremeskel S, Johnston B. Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. Oncotarget. 2015;6(39):41600–41619. doi:10.18632/oncotarget.6113.
   PubMedGoogle Scholar
• Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008;15(1):3–12. doi:10.1038/sj.cdd.4402269.
   PubMed Web of Science ®Google Scholar
• Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. 2011;11(7):802–807. doi:10.1016/j.intimp.2011.01.003.
   PubMed Web of Science ®Google Scholar
• Chavan R, Salvador D, Gustafson MP, Dietz AB, Nevala W, Markovic SN. Untreated stage IV melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity. Cancer Immunol Res. 2014;2(3):241–248. doi:10.1158/2326-6066.CIR-13-0094.
   PubMed Web of Science ®Google Scholar
• Plitas G, Rudensky AY. Regulatory T cells in cancer. Ann Rev Cancer Biol. 2020;4(1):459–477. doi:10.1146/annurev-cancerbio-030419-033428.
   Google Scholar
• Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubat T, Yagita H, Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765–772. doi:10.1093/intimm/8.5.765.
   PubMed Web of Science ®Google Scholar
• Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol. 2015;25(1):11–17. doi:10.1016/j.semradonc.2014.07.005.
   PubMed Web of Science ®Google Scholar